JP6365988B2 - 抗癌剤候補の相対的有効性の自動判定のためのシステム及び方法 - Google Patents

抗癌剤候補の相対的有効性の自動判定のためのシステム及び方法 Download PDF

Info

Publication number
JP6365988B2
JP6365988B2 JP2015510444A JP2015510444A JP6365988B2 JP 6365988 B2 JP6365988 B2 JP 6365988B2 JP 2015510444 A JP2015510444 A JP 2015510444A JP 2015510444 A JP2015510444 A JP 2015510444A JP 6365988 B2 JP6365988 B2 JP 6365988B2
Authority
JP
Japan
Prior art keywords
drug
test
optical density
database
well
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015510444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524046A (ja
Inventor
マシュー パーリー
マシュー パーリー
アラン イー ハルクイスト
アラン イー ハルクイスト
オリヴィエ ペティット
オリヴィエ ペティット
Original Assignee
ピエリアン バイオサイエンシーズ リミテッド ライアビリティ カンパニー
ピエリアン バイオサイエンシーズ リミテッド ライアビリティ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49514877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6365988(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ピエリアン バイオサイエンシーズ リミテッド ライアビリティ カンパニー, ピエリアン バイオサイエンシーズ リミテッド ライアビリティ カンパニー filed Critical ピエリアン バイオサイエンシーズ リミテッド ライアビリティ カンパニー
Publication of JP2015524046A publication Critical patent/JP2015524046A/ja
Application granted granted Critical
Publication of JP6365988B2 publication Critical patent/JP6365988B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/59—Transmissivity
    • G01N21/5907—Densitometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/90—Programming languages; Computing architectures; Database systems; Data warehousing

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Computing Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Software Systems (AREA)
  • Databases & Information Systems (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2015510444A 2012-05-02 2013-05-02 抗癌剤候補の相対的有効性の自動判定のためのシステム及び方法 Active JP6365988B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261641610P 2012-05-02 2012-05-02
US61/641,610 2012-05-02
US13/803,623 US9476871B2 (en) 2012-05-02 2013-03-14 System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
US13/803,623 2013-03-14
PCT/US2013/039189 WO2013166233A1 (en) 2012-05-02 2013-05-02 System and method for automated determination of the relative effectiveness of anti-cancer drug candidates

Publications (2)

Publication Number Publication Date
JP2015524046A JP2015524046A (ja) 2015-08-20
JP6365988B2 true JP6365988B2 (ja) 2018-08-01

Family

ID=49514877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015510444A Active JP6365988B2 (ja) 2012-05-02 2013-05-02 抗癌剤候補の相対的有効性の自動判定のためのシステム及び方法

Country Status (23)

Country Link
US (3) US9476871B2 (es)
EP (2) EP4134962A1 (es)
JP (1) JP6365988B2 (es)
KR (1) KR102028711B1 (es)
CN (1) CN104412270B (es)
AU (2) AU2013256248B2 (es)
BR (1) BR112014027287A2 (es)
CA (1) CA2872109C (es)
CL (1) CL2014002981A1 (es)
CO (1) CO7190233A2 (es)
CR (1) CR20140551A (es)
CU (1) CU20140125A7 (es)
HK (1) HK1203670A1 (es)
IL (1) IL235455B (es)
MX (1) MX345540B (es)
NI (1) NI201400128A (es)
NZ (1) NZ702526A (es)
PE (1) PE20150299A1 (es)
PH (1) PH12014502687A1 (es)
RU (1) RU2014148543A (es)
SG (1) SG11201407141VA (es)
TW (1) TWI605413B (es)
WO (1) WO2013166233A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9476871B2 (en) * 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
BR112014028396A2 (pt) * 2012-05-15 2018-05-29 Diatech Oncology processo de isolamento/purificação de célula de tumor e métodos para uso da mesma
US9460407B2 (en) * 2013-05-03 2016-10-04 Sap Se Generating graphical representations of data
WO2015171848A2 (en) * 2014-05-08 2015-11-12 Diatech Oncology, Llc Synergism and antagonism between multiple anti-cancer agents determined by mick assay
JP6521528B2 (ja) * 2016-04-18 2019-05-29 富士フイルム株式会社 代替医薬品検索装置及び代替医薬品検索方法
US11151604B2 (en) * 2016-06-10 2021-10-19 International Business Machines Corporation Revenue management using dynamic customer selection
CN110047562B (zh) * 2019-05-14 2021-04-27 上海上药第一生化药业有限公司 一种基于酶活力测定法的效价检测的信息化结构和方法
US20200388355A1 (en) * 2019-06-07 2020-12-10 Cary A. Presant Method and devices for direct apoptosis assay of purified cells

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068181A (en) 1989-12-01 1991-11-26 Akzo N.V. Method of monitoring reagent delivery in a scanning spectrophotometer
US5356793A (en) 1990-03-15 1994-10-18 Nitta Gelatin Inc. Method for testing the sensitivity of anticancer drug
US6077684A (en) 1996-11-14 2000-06-20 Vanderbilt University Automated assay for measuring apoptosis in cell culture
CN1220395A (zh) * 1997-12-15 1999-06-23 中国科学院生物物理研究所 一种基于微量元素分布特征的抗癌药物筛选方法
US6448030B1 (en) 2000-02-18 2002-09-10 University Of Nevada-Las Vegas Method for predicting the efficacy of anti-cancer drugs
WO2002040702A2 (en) * 2000-11-09 2002-05-23 Vanderbilt University Methods for the treatment of cancer and other diseases and methods of developing the same
WO2002046750A2 (en) 2000-11-13 2002-06-13 Vanderbilt University Methods of predicting chemotherapy response
EP1344060A4 (en) 2000-11-17 2004-12-22 Alfred E Slanetz METHOD FOR DETERMINING THE FUNCTION OF TARGETS AND IDENTIFYING SERIAL HEADS OF DRUGS
US20050118600A1 (en) 2002-03-13 2005-06-02 Yuko Aoki Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
US6900058B2 (en) 2003-03-11 2005-05-31 Bionostics, Inc. Control solution for photometric analysis
JP2008536128A (ja) * 2005-04-09 2008-09-04 セル バイオサイエンシズ，インコーポレイテッド 自動化微小体積アッセイシステム
CN1954887A (zh) * 2005-10-28 2007-05-02 中国科学院大连化学物理研究所 一种体外抗癌药物筛选模型的制备方法
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
KR100721927B1 (ko) 2006-10-31 2007-05-28 이수앱지스 주식회사 암조직에서 암세포를 분리하는 방법
GB2474613A (en) 2008-07-10 2011-04-20 Nodality Inc Methods and apparatus related to management of experiments
EP2443427B1 (en) * 2009-06-17 2014-04-02 Ingeneron, Inc. Method and apparatus for quantitative microimaging
KR101533469B1 (ko) 2010-02-03 2015-07-02 연세대학교 산학협력단 Ｒａｓ의 Ｔｈｒ-144번과 Ｔｈｒ-148번의 인산화의 감지를 통한 암 진단 방법, 항암제 스크리닝 및 약효테스트 방법
US20110244503A1 (en) * 2010-03-31 2011-10-06 Perree Mathieu System and Method for Anti-Cancer Drug Candidate Evaluation
US8475739B2 (en) * 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9476871B2 (en) 2012-05-02 2016-10-25 Diatech Oncology Llc System and method for automated determination of the relative effectiveness of anti-cancer drug candidates
BR112014028396A2 (pt) 2012-05-15 2018-05-29 Diatech Oncology processo de isolamento/purificação de célula de tumor e métodos para uso da mesma

Also Published As

Publication number Publication date
TW201349161A (zh) 2013-12-01
NI201400128A (es) 2015-11-24
NZ702526A (en) 2017-05-26
WO2013166233A1 (en) 2013-11-07
KR102028711B1 (ko) 2019-10-04
EP2847701A4 (en) 2016-01-06
CO7190233A2 (es) 2015-02-19
EP4134962A1 (en) 2023-02-15
PH12014502687A1 (en) 2015-01-26
AU2013256248B2 (en) 2018-10-04
MX345540B (es) 2017-02-03
CA2872109C (en) 2019-08-20
JP2015524046A (ja) 2015-08-20
BR112014027287A2 (pt) 2017-08-08
HK1203670A1 (en) 2015-10-30
CN104412270A (zh) 2015-03-11
TWI605413B (zh) 2017-11-11
CN104412270B (zh) 2018-03-20
KR20150023337A (ko) 2015-03-05
AU2013256248A1 (en) 2015-01-15
PE20150299A1 (es) 2015-02-25
EP2847701A1 (en) 2015-03-18
AU2018282460A1 (en) 2019-01-24
AU2018282460B2 (en) 2020-12-10
CU20140125A7 (es) 2015-05-28
CA2872109A1 (en) 2013-11-07
US10488402B2 (en) 2019-11-26
CR20140551A (es) 2015-02-23
CL2014002981A1 (es) 2015-09-11
US9476871B2 (en) 2016-10-25
RU2014148543A (ru) 2016-06-27
US20170219563A1 (en) 2017-08-03
MX2014013271A (es) 2015-04-08
SG11201407141VA (en) 2014-11-27
US20140141462A1 (en) 2014-05-22
US20200249222A1 (en) 2020-08-06
IL235455B (en) 2018-03-29

Similar Documents

Publication Publication Date Title
JP6365988B2 (ja) 抗癌剤候補の相対的有効性の自動判定のためのシステム及び方法
Murff et al. Does this patient have a family history of cancer?: an evidence-based analysis of the accuracy of family cancer history
Ilyas et al. Guidelines and considerations for conducting experiments using tissue microarrays
Moatamed et al. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer
Burton et al. Closing the UK care home data gap–methodological challenges and solutions
US10755806B2 (en) Graphical presentation of medical data
US20080243394A1 (en) System, method and computer program product for manipulating theranostic assays
JP2014528080A (ja) 生化学データ分析システム及び方法
CN111406294B (zh) 自动生成用于实验室仪器的规则
Quo et al. Development of a laboratory information system for cancer collaboration projects
KR102580747B1 (ko) 의료 기기, 의료 검사 요청 제어 시스템, 의료 검사 요청 제어 방법 및 기록 매체에 저장된 프로그램
Berry et al. A new resource for pathology informatics: The New Mexico decedent image database
Munir et al. National External Quality Assurance Program Pakistan (NEQAPP)–a milestone in proficiency testing in Pakistan
Miller et al. Error reduction and diagnostic concordance in breast pathology
Ferrario et al. Health Technology Assessment in Laboratory Medicine
Lessard et al. Predictive Analytics to Support Real-Time Management in Pathology Facilities
Alenazi et al. The Role of Laboratory Information System in Improving the Delivery of Laboratory Services: A Recent Systematic Review
Moher et al. Measuring the Quality of Breast Cancer Care in Women: Summary
Nofech-Mozes et al. Synoptic Reporting on Breast Cancer Biomarkers: A Novel Quality Improvement Module.
CN116935950A (zh) 一种精准医学分子遗传实验室智能化综合管理系统
Betigeri Quality design in anatomical pathology
Peter et al. Biomarkers and Oncology

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160502

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170130

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180523

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180622

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180622

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180622

R150 Certificate of patent or registration of utility model

Ref document number: 6365988

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250